CoChat

Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells

Open access
Chen, Pan-Yu, Muzumdar, Mandar Deepak, Dorans, Kimberly Judith, Robbins, Rebecca, Bhutkar, Arjun, del Rosario, Amanda, Mertins, Philipp, Qiao, Jana, Schafer, Anette Claudia, Gertler, Frank, Carr, Steven, Jacks, Tyler · 2018 · Cancer Research
Cited by 46

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Activating mutations in KRAS are the hallmark genetic alterations in pancreatic ductal adenocarcinoma (PDAC) and the key drivers of its initiation and progression. Longstanding efforts to develop novel KRAS inhibitors have been based on the assumption that PDAC cells are addicted to activated KRAS, but this assumption remains controversial. In this study, we analyzed the requirement of endogenous Kras to maintain survival of murine PDAC cells, using an inducible shRNA-based system that enables temporal control of Kras expression. We found that the majority of murine PDAC cells analyzed tolerated acute and sustained Kras silencing by adapting to a reversible cell state characterized by differences in cell morphology, proliferative kinetics, and tumor-initiating capacity. While we observed no significant mutational or transcriptional changes in the Kras-inhibited state, global phosphoproteomic profiling revealed significant alterations in cell signaling, including increased phosphorylation of focal adhesion pathway components. Accordingly, Kras-inhibited cells displayed prominent focal adhesion plaque structures, enhanced adherence properties, and increased dependency on adhesion for viability in vitro. Overall, our results call into question the degree to which PDAC cells are addicted to activated KRAS, by illustrating adaptive nongenetic and nontranscriptional mechanisms of resistance to Kras blockade. However, by identifying these mechanisms, our work also provides mechanistic directions to develop combination strategies that can help enforce the efficacy of KRAS inhibitors. Significance: These results call into question the degree to which pancreatic cancers are addicted to KRAS by illustrating adaptive nongenetic and nontranscriptional mechanisms of resistance to Kras blockade, with implications for the development of KRAS inhibitors for PDAC treatment. Cancer Res; 78(4); 985–1002. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-2129

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 46

Metadata

Authors
Chen, P.-Y., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A., del Rosario, A., Mertins, P., Qiao, J., Schafer, A. C., Gertler, F., Carr, S., & Jacks, T.
Venue
Cancer Research
Published
2018-02-14
Volume
78
Issue
4
Pages
985-1002
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2776458885
Cited by
46
References
20
FWCI
2.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-2129
The paper
Chen, P.-Y., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A., del Rosario, A., Mertins, P., Qiao, J., Schafer, A. C., Gertler, F., Carr, S., & Jacks, T. (2018). Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-2129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.